谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Efficacy and Safety of Switching from Reference Adalimumab to CT-P17 (100 Mg/ml): 52-Week Randomized, Double-Blind Study in Rheumatoid Arthritis

Daniel E. Furst,Janusz Jaworski,Rafal Wojciechowski,Piotr Wiland,Anna Dudek,Marek Krogulec,Slawomir Jeka,Agnieszka Zielinska,Jakub Trefler,Katarzyna Bartnicka-Maslowska,Magdalena Krajewska-Wlodarczyk,Piotr A. Klimiuk,Sang Joon Lee,Sung Hyun Kim,Yun Ju Bae,Go Eun Yang,Jae Kyoung Yoo,Jonathan Kay,Edward Keystone

Rheumatology（2021）

引用 12|浏览40
关键词
adalimumab,biosimilar,CT-P17,efficacy,immunogenicity,rheumatoid arthritis,safety,switching,tumour necrosis factor inhibitors
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要